News | July 29, 2024
Dr Reddys Laboratories posts Q1 FY25 consolidated PAT at Rs. 1,392 Cr
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Shilpa Biologicals has developed high concentration adalimumab (100 mg/mL)
Contepo offers a unique mechanism of action and has the potential to address increasing antibiotic resistance and gaps in the current antibiotic treatment landscape
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Subscribe To Our Newsletter & Stay Updated
